Sickle cell disease, a genetic disorder of hemoglobin, affects around 1 in 500 African American children and about 1 in 36,000 Hispanic-American children. A painful vaso-occlusive crisis is reported as the most common reason for emergency department visits and hospitalization among sickle cell disease patients. To combat the disease and improve the quality of life of the affected individuals, there is increased focus on the development of investigational drugs that can reduce the frequency and severity of vaso occlusive crisis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing vaso occlusive crisis associated with sickle cell disease pipeline development activities.
Drug therapy is primarily used for acute sickle cell crises. Opioid analgesics, hydration, cognitive and behavioral therapies, and rest comprise the standard treatment approach for managing vaso occlusive crisis. Since the basic strategy to treat sickle cell crisis is symptomatic with escalating doses of opioid and non-opioid medications, there is a need for targeted therapies that prevent or effectively reduce the frequency of vaso occlusive crisis and offer long-term relief to the patients.
This product will be delivered within 3-5 business days.
Report Coverage
The Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline Report by the publisher gives comprehensive insights into vaso occlusive crisis associated with sickle cell disease drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vaso occlusive crisis associated with sickle cell disease. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The vaso occlusive crisis associated with sickle cell disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vaso occlusive crisis associated with sickle cell disease.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing vaso occlusive crisis associated with sickle cell disease pipeline development activities.
Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline Outlook
Vaso occlusive crisis represents the most common clinical manifestation of sickle cell disease, with nearly half of the patients affected by these pain episodes. It is caused when sickled red blood cells obstruct the microcirculation, resulting in ischemic injury and pain. The frequency of vaso occlusive crisis is observed to be extremely variable and the pain can affect any part of the body.Drug therapy is primarily used for acute sickle cell crises. Opioid analgesics, hydration, cognitive and behavioral therapies, and rest comprise the standard treatment approach for managing vaso occlusive crisis. Since the basic strategy to treat sickle cell crisis is symptomatic with escalating doses of opioid and non-opioid medications, there is a need for targeted therapies that prevent or effectively reduce the frequency of vaso occlusive crisis and offer long-term relief to the patients.
Vaso Occlusive Crisis Associated With Sickle Cell Disease - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vaso occlusive crisis associated with sickle cell disease drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The vaso occlusive crisis associated with sickle cell disease therapeutic assessment report covers 50+ drug analyses based on drug classes:
- Antibody
- Antisense Oligonucleotides
- Immunotherapy
- Monoclonal Antibody
- Peptides
- Protein
- Recombinant Protein
- Small Molecule
- Stem Cell
- Vaccine
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Vaso Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Assessment Segmentation, By Phases
The vaso occlusive crisis associated with sickle cell disease report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for vaso occlusive crisis associated with sickle cell disease.Vaso Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under vaso occlusive crisis associated with sickle cell disease pipeline analysis include antibody, antisense oligonucleotides, immunotherapy, monoclonal antibody, peptides, protein, recombinant protein, small molecule, stem cell, and vaccine. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vaso occlusive crisis associated with sickle cell disease.Vaso Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials Therapeutic Assessment - Competitive Dynamics
The vaso occlusive crisis associated with sickle cell disease drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vaso occlusive crisis associated with sickle cell disease clinical trials:- Pfizer
- Hoffmann-La Roche
- Novartis Pharmaceuticals
- Beam Therapeutics Inc.
- Forma Therapeutics, Inc.
Vaso Occlusive Crisis Associated With Sickle Cell Disease - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vaso occlusive crisis associated with sickle cell disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vaso occlusive crisis associated with sickle cell disease drug candidates.Biological: Crizanlizumab
Sponsored by Novartis Pharmaceuticals, the objective of this multi-center, randomized, Phase III study is to investigate the safety and efficacy of crizanlizumab (5 mg/kg), a monoclonal antibody medication, compared to placebo in an estimated 315 adolescent and adult patients with sickle cell disease experiencing frequent vaso-occlusive crises.Drug: Lidocaine IV
This Phase II interventional study aims to assess vaso occlusive crisis associated with sickle cell disease drug candidate IV lidocaine as an adjunct medication to opioid treatment to reduce opioid requirements and manage pain in patients visiting the emergency departments due to sickle cell crisis. The clinical trial has enrolled around 100 patients and is expected to be completed by June 2025.Reasons To Buy This Report
The Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vaso occlusive crisis associated with sickle cell disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into vaso occlusive crisis associated with sickle cell disease collaborations, regulatory environments, and potential growth opportunities.Key Questions Answered in the Vaso Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Insight Report
- Which companies/institutions are leading the vaso occlusive crisis associated with sickle cell disease drug development?
- What is the efficacy and safety profile of vaso occlusive crisis associated with sickle cell disease pipeline drugs?
- Which company is leading the vaso occlusive crisis associated with sickle cell disease pipeline development activities?
- What is the current vaso occlusive crisis associated with sickle cell disease commercial assessment?
- What are the opportunities and challenges present in the vaso occlusive crisis associated with sickle cell disease drug pipeline landscape?
- What is the efficacy and safety profile of vaso occlusive crisis associated with sickle cell disease pipeline drugs?
- Which company is conducting major trials for vaso occlusive crisis associated with sickle cell disease drugs?
- Which companies/institutions are involved in vaso occlusive crisis associated with sickle cell disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in vaso occlusive crisis associated with sickle cell disease?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Vaso Occlusive Crisis Associated With Sickle Cell Disease
4 Patient Profile: Vaso Occlusive Crisis Associated With Sickle Cell Disease
5 Vaso Occlusive Crisis Associated With Sickle Cell Disease: Epidemiology Snapshot
6 Vaso Occlusive Crisis Associated With Sickle Cell Disease: Market Dynamics
7 Vaso Occlusive Crisis Associated With Sickle Cell Disease: Key Facts Covered
8 Vaso Occlusive Crisis Associated With Sickle Cell Disease, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Vaso Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Vaso Occlusive Crisis Associated With Sickle Cell Disease, Key Drug Pipeline Companies
